Target
Kallikrein-1
Ligand
BDBM345105
Substrate
n/a
Meas. Tech.
Kallikrein Assay
IC50
25.1±n/a nM
Citation
 Liu, WEdmondson, SDGuo, ZMertz, EOgawa, AKSo, SSun, WBrockunier, LLAli, AKuang, RWu, H Factor Xla inhibitors US Patent  US9783530 Publication Date 10/10/2017 
Target
Name:
Kallikrein-1
Synonyms:
KLK1 | KLK1_HUMAN | Kallikrein 1 | Kallikrein-1 | Kidney/pancreas/salivary gland kallikrein | Tissue kallikrein
Type:
Enzyme
Mol. Mass.:
28874.69
Organism:
Homo sapiens (Human)
Description:
P06870
Residue:
262
Sequence:
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS
  
Inhibitor
Name:
BDBM345105
Synonyms:
4-[(2-{5-[3-chloro-2- fluoro-6-(1H-tetrazol-1- yl)phenyl]-1- oxidopyridin-2-yl}-3- cyclopropylpropanoyl) amino]benzoic acid | US9783530, 50
Type:
Small organic molecule
Emp. Form.:
C25H20ClFN6O4
Mol. Mass.:
522.916
SMILES:
OC(=O)c1ccc(NC(=O)C(CC2CC2)c2ccc(c[n+]2[O-])-c2c(F)c(Cl)ccc2-n2cnnn2)cc1
Structure:
Search PDB for entries with ligand similarity: